18 results
6-K
EX-99.1
ZLAB
Zai Lab Limited
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
in the placebo arm, with significantly reduced the risk of disease progression or death of 85% (hazard ratio of 0.15, p<0.0001). Secondary endpoints … in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36).
The most common adverse reactions (≥20%) were alopecia, fatigue, nausea
8-K
EX-99.1
ZLAB
Zai Lab Limited
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
was 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% (hazard ratio of 0.15, p … compared to 6.6 months in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36).
Important Safety Information
8-K
EX-99.1
ZLAB
Zai Lab Limited
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
with niraparib compared to placebo: 24.8 months versus 8.3 months, hazard ratio (HR), 0.45; p<0.001. Other pre-specified efficacy results included … was 12.1 months, compared with 7.9 months for the matched-control patients in EF-14 (hazard ratio=0.46, p=0.033).
mOS was 25.2 months, compared with 15.9
6-K
EX-99.1
ZLAB
Zai Lab Limited
22 Oct 18
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
7:48am
of disease progression or death by 73% in patients with germline BRCA mutations (hazard ratio (HR) 0.27) and by 55% in patients without germline BRCA mutations
6-K
EX-99.1
ZLAB
Zai Lab Limited
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
. Clinically meaningful reduction in risk of disease progression or death was further demonstrated with hazard ratios (HRs) of 0.40, 0.43 and 0.68
6-K
EX-99.1
5kckh52gvs0laowouf5
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
aluj7dxtijunz v5t4m
27 Dec 19
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
7:51am
6-K
EX-99.1
quwjhkbet4a 9z7
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
20-F
4etpt6
30 Apr 18
Annual report (foreign)
9:07am
10-K
EX-10.33
qywm nggo16tpk67h2s
1 Mar 21
Annual report
12:00am
10-K
EX-10.32
8w69p
1 Mar 21
Annual report
12:00am
10-K
ppq4931q
1 Mar 21
Annual report
12:00am
- Prev
- 1
- Next